Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT

Kim Donoghue,1,2* Sadie Boniface,2,3 Eileen Brobbin,2 Sarah Byford,4 Rachel Coleman,5 Simon Coulton,6 Edward Day,7 Ranjita Dhital,2,8 Anum Farid,2,9 Laura Hermann,2,5 Amy Jordan,2,10 Andreas Kimergård,2 Maria-Leoni Koutsou,11 Anne Lingford-Hughes,12 John Marsden,2,13 Joanne Neale,2 Aimee O’Neill,14 Thomas Phillips,5 James Shearer,4 Julia Sinclair,14 Joanna Smith,14 John Strang,2,13 John Weinman,15 Cate Whittlesea,16 Kideshini Widyaratna17 and Colin Drummond2,13

1Research Department of Clinical, Educational and Health Psychology, University College London, London, UK
2National Addictions Centre, Addictions Department, Institute of Psychiatry, Psychology and Neuroscience King’s College London, London, UK
3Institute of Alcohol Studies, London, UK
4Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
5Faculty of Health Sciences, Institute for Clinical and Applied Health Research (ICAHR), University of Hull, Hull, UK
6Centre for Health Services Studies, University of Kent, Canterbury, Kent, UK
7Institute for Mental Health, University of Birmingham, Birmingham, UK
8Arts and Sciences Department, University College London, London, UK
9What Works for Children’s Social Care, London, UK
10Black Country Healthcare NHS Foundation Trust, West Bromwich, UK
11Tavistock and Portman NHS Foundation Trust, London, UK
12Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK
13South London and Maudsley NHS Foundation Trust, London, UK
14Faculty of Medicine, University of Southampton, Southampton, UK
15School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
16Research Department of Practice and Policy, UCL School of Pharmacy, University College London, London, UK
17Institute of Psychiatry Psychology and Neuroscience, Department of Psychology, King’s College London, London, UK

*Corresponding author. k.donoghue@wellcome.ac.uk
Disclosure of interests

**Full disclosure of interests:** Completed ICMJE forms for all authors, including all related interests, are available in the toolkit on the NIHR Journals Library report publication page at https://doi.org/10.3310/DQKL6124.

**Primary conflicts of interest:** Sadie Boniface was joint PI on an NIHR Policy Research Programme award in 2021 (NIHR202711) and works at the Institute of Alcohol Studies the Alliance House Foundation, and other academic and civil society organisations.

Anne Lingford-Hughes has received Honoraria paid into her Institutional funds for speaking and Chairing engagements from Lundbeck, Janssen-Cilag; received research grants or support from Lundbeck, GSK; unrestricted funds support from Alcarelle for a PhD, consultancy for Silence (paid) and Dobin, Britannia Pharmaceuticals and AstraZeneca (all unpaid); delivered training for British Association for Psychopharmacology about alcoholism treatment.

John Marsden declares research grants from the NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Mental Health Foundation Trust (SLaM; randomised controlled trial of novel cognitive therapy for cocaine use disorder). John Marsden is a clinical academic consultant for the US National Institute on Drug Abuse, Centre for Clinical Trials Network and he was Senior Academic Advisor for the Alcohol, Drug, Tobacco, Justice Division, Health Improvement, Public Health England (to September 2021). He received honoraria and travel support from PCM Scientific and Martindale for the Improving Outcomes in Treatment of Opioid Dependence conference (2018 and 2021).

John Strang is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. John Strang has been in receipt of an NIHR Senior Investigator Award.

Joanne Neale is part funded by the NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London.

Colin Drummond is supported by the NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. CD is in receipt of an NIHR Senior Investigator Award. CD was part funded by the NIHR Collaboration for Leadership in Applied Health Research and Care South London (NIHR CLAHRC South London) now recommissioned as NIHR Applied Research Collaboration South London at King’s College Hospital NHS Foundation Trust. CD has also received research funding from the NIHR and the Medical Research Council.

Eileen Brobbin is completing a PhD funded by the NIHR Applied Research Collaboration South London at King’s College Hospital NHS Foundation Trust.

Laura Hermann is in receipt of an NIHR Pre-doctoral Fellowship.
Plain language summary

Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT

DOI: 10.3310/DQKL6124
Plain language summary

What is the problem?

Many people who are trying to stop drinking alcohol can find it difficult to remain alcohol free. There is a medication called acamprosate (Campral) that can reduce cravings thereby increasing the likelihood of abstinence. However, some people have trouble taking the right amount of acamprosate tablets needed every day at the right time, preferably at mealtimes. This means the medication is not as effective. We have tested some new ways to help support people taking acamprosate.

What did we do?

We tested three different strategies to find the best way to support people taking acamprosate. We recruited 739 people aged 18 and over who were receiving alcohol treatment to stop drinking and were taking acamprosate. We randomly allocated these people to three groups. The first was Standard Support, the usual support people receive when taking acamprosate. The second group received Standard Support plus Medication Management. This consisted of 12 telephone calls over 6 months with a trained pharmacist to discuss the importance of taking the right amount of the medication, how the medication works and strategies to help people take the medication correctly. The third group received Standard Support, Medication Management and Contingency Management. This involved giving people shopping vouchers for participating with Medication Management calls. The maximum value of vouchers per person was £120.

What did we find out?

People who were in the group receiving Medication Management and Contingency Management took a greater number of acamprosate tablets. We also found that Medication Management plus Contingency Management was more cost-effective; there were greater gains in health with a smaller cost per person compared to Standard Support alone. This shows that there is likely to be a benefit to patients of Medication Management plus Contingency Management for supporting people taking acamprosate.
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)

Impact factor: 3.6

Launched in 1997, Health Technology Assessment (HTA) has an impact factor of 3.6 and is ranked 32nd (out of 105 titles) in the ‘Health Care Sciences & Services’ category of the Clarivate 2021 Journal Citation Reports (Science Edition). It is also indexed by MEDLINE, CINAHL (EBSCO Information Services, Ipswich, MA, USA), Embase (Elsevier, Amsterdam, the Netherlands), NCBI Bookshelf, DOAJ, Europe PMC, the Cochrane Library (John Wiley & Sons, Inc., Hoboken, NJ, USA), INAHTA, the British Nursing Index (ProQuest LLC, Ann Arbor, MI, USA), Ulrichsweb™ (ProQuest LLC, Ann Arbor, MI, USA) and the Science Citation Index Expanded™ (Clarivate™, Philadelphia, PA, USA).

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta.

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 13/86/03. The contractual start date was in December 2014. The draft report began editorial review in December 2021 and was accepted for publication in August 2022. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health and Care Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care.

Copyright © 2023 Donoghue et al. This work was produced by Donoghue et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.

For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Newgen Digitalworks Pvt Ltd, Chennai, India (www.newgen.co).
NIHR Journals Library Editor-in-Chief

Dr Cat Chatfield  Director of Health Services Research UK

NIHR Journals Library Editors

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HSDR, PGfAR, PHR journals) and Editor-in-Chief of HSDR, PGfAR, PHR journals

Dr Peter Davidson  Interim Chair of HTA and EME Editorial Board, Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Consultant in Public Health, Delta Public Health Consulting Ltd, UK

Ms Tara Lamont  Senior Adviser, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery  Professor of Health Technology Assessment, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Dr Rob Riemsma  Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Professor Helen Roberts  Professor of Child Health Research, Child and Adolescent Mental Health, Palliative Care and Paediatrics Unit, Population Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact:  journals.library@nihr.ac.uk